[The platelet inhibitor problem].
Some problems encountered in interpreting randomized clinical trials on the secondary prevention of myocardial infarction and transient cerebral ischemic attacks are discussed. With regard to acetylsalicylic acid, the dosage, and some general side effects such as those observed in transfusions, are considered.
D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use*; D001803:Blood Transfusion; D002545:Brain Ischemia / Q000517:prevention & control; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D008297:Male; D009203:Myocardial Infarction / Q000517:prevention & control*; D010974:Platelet Aggregation / Q000187:drug effects*; D012008:Recurrence; D013442:Sulfinpyrazone / Q000009:adverse effects / Q000627:therapeutic use*
D001241:Aspirin; D013442:Sulfinpyrazone
Das Plättchenhemmer-Problem.